A5039252979- Bariatric Surgery and Outcomes
- Diabetes Treatment and Management
- Diet and metabolism studies
- Metabolism, Diabetes, and Cancer
- Gastric Cancer Management and Outcomes
- Obesity and Health Practices
- Cardiovascular Function and Risk Factors
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pancreatic function and diabetes
- Regulation of Appetite and Obesity
- Diabetes Management and Research
- Obesity, Physical Activity, Diet
- Clinical Laboratory Practices and Quality Control
- Health Systems, Economic Evaluations, Quality of Life
- Adipose Tissue and Metabolism
- Biosimilars and Bioanalytical Methods
- Body Contouring and Surgery
- Statistical Methods in Clinical Trials
- Dietary Effects on Health
- Pesticide Residue Analysis and Safety
- SARS-CoV-2 detection and testing
- Nuclear Receptors and Signaling
- Chronic Disease Management Strategies
- Sleep and Work-Related Fatigue
- GDF15 and Related Biomarkers
Copenhagen University Hospital
2015-2025
Hvidovre Hospital
2015-2024
Gentofte Hospital
2018-2023
Herlev Hospital
1987-2022
University of Copenhagen
2011-2019
Novo Nordisk Foundation
2012-2019
Rigshospitalet
2016
Novo Nordisk (India)
2015
Glostrup Hospital
2015
Amager Hospital
2013
Our aim was to study the potential mechanisms responsible for improvement in glucose control Type 2 diabetes (T2D) within days after Roux-en-Y gastric bypass (RYGB). Thirteen obese subjects with T2D and twelve matched normal tolerance (NGT) were examined during a liquid meal before (Pre), 1 wk, 3 mo, yr RYGB. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent-insulinotropic polypeptide (GIP), glucagon concentrations measured. Insulin resistance (HOMA-IR), β-cell...
Roux-en-Y gastric bypass (RYGB) is an effective means to achieve sustained weight loss for morbidly obese individuals. Besides rapid reduction, patients major improvements of insulin sensitivity and glucose homeostasis. Dysbiosis gut microbiota has been associated with obesity some its co-morbidities, like type 2 diabetes, changes microbial communities have hypothesized mediate part the beneficial metabolic effects observed after RYGB. Here we describe in taxonomic composition functional...
β-Cell function improves in patients with type 2 diabetes response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has been linked the exaggerated secretion of glucagon-like peptide 1 (GLP-1), but causality not established. The aim this study was investigate role GLP-1 improving β-cell and tolerance regulating glucagon release RYGB using exendin(9-39) (Ex-9), a receptor (GLP-1R)-specific antagonist. Nine were examined before week 3 months Each visit consisted...
Roux-en-Y gastric bypass (RYGB) improves glycemic control within days after surgery, and changes in insulin sensitivity β-cell function are likely to be involved. We studied 10 obese patients with type 2 diabetes (T2D) glucose-tolerant subjects before 1 week, 3 months, year RYGB. Participants were included a preoperative diet-induced total weight loss of -9.2 ± 1.2%. Hepatic peripheral assessed using the hyperinsulinemic- euglycemic clamp combined glucose tracer technique, was evaluated...
Roux-en-Y gastric bypass (RYGB) causes extensive changes in gastrointestinal anatomy and leads to reduced appetite large weight loss, which partly is due an exaggerated release of anorexigenic gut hormones.To examine whether the altered passage foods through tract after RYGB could be responsible for hormone release, we studied motility with a scintigraphic technique as well secretion hormones glucagon-like peptide (GLP)-1 YY3-36 (PYY3-36 ) 17 patients>1 year nine healthy control subjects.At...
Bile acids and fibroblast growth factor 19 (FGF19) have been suggested as key mediators of the improvements in glucose metabolism after Roux-en-Y gastric bypass (RYGB). To describe fasting postprandial state total bile acid (TBA) FGF19 concentrations before RYGB relate them to parameters metabolism, glucagon-like peptide-1, cholecystokinin, cholesterol fractions. A prospective descriptive study was performed at Department Endocrinology, Hvidovre Hospital, Hvidovre, Denmark. Thirteen type 2...
Obesity-related diseases affect half of the global population, and bariatric surgery is one few interventions with long-lasting weight loss cardio-metabolic effects. Here, we investigated effect Roux-en-Y gastric bypass on plasma proteome, hypothesizing that specific proteins or protein patterns may serve as key mediators markers metabolic response. We performed mass spectrometry (MS)-based proteomics two longitudinal studies encompassing 47 morbidly obese patients, generating quantitative...
The aim of this study was to develop new and useful criteria for partitioning reference values into subgroups applicable gaussian distributions that can be transformed distributions.The proposed relate percentages the outside each limits combined distribution. Critical suggested as these were derived from analytical bias quality specifications using common intervals throughout a geographic area. As alternative actual percentages, mathematically critical distances between subgroup...
Aims To evaluate the performances of commercially available glucagon‐like peptide‐1 (GLP‐1) assays and implications for clinical studies. Methods Known concentrations (5–300 pmol/l) synthetic GLP‐1 isoforms (GLP‐1 1‐36NH 2 , 7‐36NH 9‐36NH 1‐37, 7‐37 9‐37) were added to matrix (assay buffer) supplied with 10 different kits human plasma, recoveries determined. Assays yielding meaningful results analysed precision sensitivity by repeated analysis ability discriminate low concentrations....
Roux-en-Y gastric bypass surgery (RYGB) in patients with type 2 diabetes often leads to early disease remission, and it is unknown what extent this involves improved pancreatic β-cell function per se and/or enhanced insulin- non-insulin-mediated glucose disposal (glucose effectiveness). We studied 30 obese patients, including 10 diabetes, 8 impaired tolerance, 12 normal tolerance before, 1 wk, 3 mo after RYGB, using an intravenous test (IVGTT) estimate first-phase insulin response,...
Exaggerated secretion of glucagon-like peptide 1 (GLP-1) is important for postprandial glucose tolerance after Roux-en-Y gastric bypass (RYGB), whereas the role glucose-dependent insulinotropic polypeptide (GIP) remains to be resolved. We aimed explore relative importance endogenously secreted GLP-1 and GIP on β-cell function RYGB. used DPP-4 inhibition enhance concentrations intact receptor antagonist exendin-(9–39) (Ex-9) specific blockage actions. Twelve glucose-tolerant patients were...
Roux-en-Y gastric bypass (RYGB) improves glucose tolerance and ameliorates fasting hyperinsulinemia within days after surgery. Improvements in hepatic insulin sensitivity clearance could contribute importantly to these effects.The objective of the investigation was study changes RYGB.This a prospective and, subgroup patients, postprandial meal test before 1 week, 3 months, year RYGB.The conducted at Hvidovre Hospital (Hvidovre, Denmark).Patients included 2 groups obese RYGB-patients: 1) type...
Obesity is characterized by low grade inflammation and an altered secretion of inflammatory cytokines from the adipose tissue. Weight loss has shown to reduce inflammation; however, changes in cytokine profiles during massive weight are not well described. The present study explored hypothesis that Roux-en-Y gastric bypass (RYGB) reduces circulating levels pro-inflammatory cytokines, while increasing anti-inflammatory obese subjects with type 2 diabetes (T2D) normal glucose tolerant (NGT)...
Enhanced secretion of glucagon-like peptide 1 (GLP-1) seems to be essential for improved postprandial β-cell function after Roux-en-Y gastric bypass (RYGB) but is less studied sleeve gastrectomy (SG). Moreover, the role other major incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), relatively unexplored bariatric surgery. We effects separate and combined GLP-1 receptor (GLP-1R) GIP (GIPR) blockade during mixed-meal tests in unoperated (CON), SG-operated, RYGB-operated...
Bariatric surgery results in marked body weight loss and improves type 2 diabetes most patients with obesity. The growth differentiation factor 15 (GDF15) has recently emerged as a novel satiety factor. To begin to understand whether GDF15 is involved mediating the effects of bariatric on glycemia humans, we measured plasma obesity ( n = 25) 22) before after Roux-en-Y gastric bypass (RYGB) surgery. was increased 1 wk RYGB compared (689 ± 45 vs. 487 28 pg/ml, P < 0.001) remained elevated...
Glucagon is secreted from pancreatic α cells, and hypersecretion (hyperglucagonemia) contributes to diabetic hyperglycemia. Molecular heterogeneity in hyperglucagonemia poorly investigated. By screening human plasma using high-resolution-proteomics, we identified several glucagon variants, among which proglucagon 1-61 (PG 1-61) appears be the most abundant form. PG subjects with obesity, both before after gastric bypass surgery, protein fat as main drivers for secretion but glucose after....